Sit A Spell

AstraZeneca has been at the forefront of the fight against breast cancer for over 30 years and is fully committed to cancer research and treatment.

AstraZeneca is also a founding member and sponsor of National Breast Cancer Awareness Month (NBCAM).

  So why am I posting this new blog?  Because the MF’s are the REASON there is cancer.  Below I have listed their original names and the products that they have manufactured through out the years.  Please note that they are the Manufacturers and PATENT HOLDERS of TAMOXIFEN which has been around since 1972 and is the ONLY medication still given today to treat pre-menapausal woman with breast cancer. (It also causes, blood clots and uterine cancer, but they have a pill for that too.) BUT it is the “STANDARD” for treatment.  They are also the makers of some of the chemo treatments as well.   Oh and their Patent expires in april 2008 for Tamoxifen so now other companies can manufacture this cancer drug too.  I think it is interesting that this company originally produced plastics that were toxic, & chemicals that are toxic.  So if I were a company making MILLIONS AND BILLIONS of dollars on plastics and chemicals that cause cancer, I think I would discover a drug to treat those cancers, than start a foundation to help support the woman who got that cancer, and than give them more drugs that I made to help them beat that cancer, and then be there for them to hold their hands and show my support, while The Doctors I gave kickbacks to to use my medications, operated on them to remove the new cancer they got from my drugs I gave them to cure their old cancer. AAAAAAARRRRRRRRGGGGGGGGGG!!!!

 AstraZeneca PLC^[1] (LSE: AZN, OMX: AZN, NYSE: AZN), is a large Anglo-Swedish pharmaceutical company formed on 6 April 1999 by the merger of Swedish Astra AB and British Zeneca Group PLC. Zeneca was part of Imperial Chemical Industries prior to a demerger in 1993.^[2][3] AstraZeneca develops, manufactures, and sells pharmaceuticals to treat disorders in the gastrointestinal, cardiac and vascular, neurological and psychiatric, infection, respiratory, pathological inflammation and oncology areas.

Sales in 2003 totalled $18.8 billion, with a profit before tax of $4.2 billion. Total R&D spending was $3.5 billion. The corporate headquarters are in London, England, the research and development (R&D) headquarters are in Södertälje, Sweden. Major R&D centres are located on three continents in the United States, United Kingdom, Sweden, and India.

 Atlas Chemical Industries

Founded as Atlas Powder Company in 1912 as a result of divestment of DuPont businesses, later changed its name and purchased The Stuart Company (which it renamed Stuart Pharmaceuticals), and was eventually acquired by Imperial Chemical Industries (ICI).

 Astra AB

Founded in 1913 near Stockholm, Sweden, incorporated as Astra USA in 1947, formed a joint venture with Merck in the 1990s, and eventually became Astra Pharmaceuticals, LP.

 Imperial Chemical Industries (ICI) / Zeneca

Founded in 1926 in the United Kingdom, established a research organization in 1967 in Stamford, Connecticut, and then a year later a business unit called ICI Americas, which acquired Atlas Chemical Industries in 1972 and moved the United States headquarters to the Fairfax campus and the Stuart Pharmaceuticals Division to offices in Concord Plaza in Wilmington, Delaware]. Changed its bioscience businesses name to Zeneca Inc in 1992, keeping the ICI branding on its chemical businesses, and then a year later demerged into two separate and independent companies.

 Stuart Pharmaceuticals

Founded as The Stuart Company in 1941 in Pasadena, California, by Arthur Hanisch, manufactured and marketed a number of innovative pharmaceutical products (including liquid multivitamin, chewable vitamin tablets, capsule-shaped tablets, effervescent laxatives, and instant liquid vitamin mix), purchased by Atlas Chemical Industries.

 Merger and acquisition activity

AstraZeneca has, following a collaborative relationship begun in 2004,^[2] commenced the acquisition of Cambridge Antibody Technology (CAT).^[3] The company is currently in the final stages of exercising compulsory acquisition options against outstanding CAT shares. On April 23, 2007 it was announced MedImmune and AstraZeneca entered into a definitive agreement under which AstraZeneca intends to acquire MedImmune in an all cash transaction at $58 per share, or about $15.2 billion. ^[4]

 Collaborations and alliances

• Bristol-Myers Squibb a world wide collaboration to develop and commercialize two investigational drugs (Saxagliptin and Dapagliflozin) beginning from 2007.^[5] * Abbott Laboratories in relation to Crestor® and TriCor®, commencing in 2006 and extending to at least 2009.^[6]
• Astex. Announced 2005. For discovery, development and commercialisation of novel small molecule inhibitors of Protein Kinase B for use as anti-cancer agents.^[7]
• Avanir. Announced 2005. For research and licensing in the area of Reverse Cholesterol Transport (RCT) enhancing compounds for the treatment of cardiovascular disease.^[8]
• Diamond Member of the Pennsylvania Bio commerce organization.^[9]
• Schering AG. Announced 2005. For research and licensing in the area of Selective Glucocorticoid Receptor Agonists (SEGRAs).